.Pharmacolibrary.Drugs.D_Dermatologicals.D11A_OtherDermatologicalPreparations.D11AH08_Abrocitinib.Abrocitinib

Information

name:Abrocitinib
ATC code:D11AH08
route:oral
n-compartments2

Abrocitinib is an oral Janus kinase 1 (JAK1) inhibitor indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. It is approved for clinical use in several regions, including the US and EU.

Pharmacokinetics

Reported from healthy adult subjects after oral administration of a single 200 mg dose in phase I studies.

References

  1. Le, M, et al., & Litvinov, IV (2021). Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. Frontiers in medicine 8 682547–None. DOI:10.3389/fmed.2021.682547 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34540860

Revisions

Generated at 2025-07-22T18:21:06Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos